Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 157 to 159 of 159 entries
Sorted by: Best Match Show Resources per page
Physician Interpretation of Data of Uncertain Clinical Utility in Oncology Prescription Drug Promotion.

The oncologist

Boudewyns V, O'Donoghue AC, Paquin RS, Aikin KJ, Ferriola-Bruckenstein K, Scott VM.
PMID: 34510619
Oncologist. 2021 Dec;26(12):1071-1078. doi: 10.1002/onco.13972. Epub 2021 Sep 28.

BACKGROUND: Little is known about how physicians interpret data displays that depict preliminary or exploratory clinical data in physician-targeted sales aids for oncology drugs. Using three factorial experiments, we examined whether disclosures of data limitations and clinical uncertainty adequately...

Cite
Boudewyns V, O'Donoghue AC, Paquin RS, et al. Physician Interpretation of Data of Uncertain Clinical Utility in Oncology Prescription Drug Promotion. Oncologist. 2021;26(12):1071-1078doi: 10.1002/onco.13972.
Boudewyns, V., O'Donoghue, A. C., Paquin, R. S., Aikin, K. J., Ferriola-Bruckenstein, K., & Scott, V. M. (2021). Physician Interpretation of Data of Uncertain Clinical Utility in Oncology Prescription Drug Promotion. The oncologist, 26(12), 1071-1078. https://doi.org/10.1002/onco.13972
Boudewyns, Vanessa, et al. "Physician Interpretation of Data of Uncertain Clinical Utility in Oncology Prescription Drug Promotion." The oncologist vol. 26,12 (2021): 1071-1078. doi: https://doi.org/10.1002/onco.13972
Boudewyns V, O'Donoghue AC, Paquin RS, Aikin KJ, Ferriola-Bruckenstein K, Scott VM. Physician Interpretation of Data of Uncertain Clinical Utility in Oncology Prescription Drug Promotion. Oncologist. 2021 Dec;26(12):1071-1078. doi: 10.1002/onco.13972. Epub 2021 Sep 28. PMID: 34510619.
Copy Download .nbib Format: NLM
Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial.

American heart journal

Cavender MA, O'Donoghue ML, Abbate A, Aylward P, Fox KA, Glaser RX, Park JG, Lopez-Sendon J, Steg PG, Sabatine MS, Morrow DA.
PMID: 34508693
Am Heart J. 2022 Jan;243:147-157. doi: 10.1016/j.ahj.2021.08.022. Epub 2021 Sep 08.

BACKGROUND: p38 mitogen activated kinase (MAPK) mediates the response to pro-inflammatory cytokines following myocardial infarction (MI) and is inhibited by losmapimod.METHODS: LATITUDE-TIMI 60 (ClinicalTrials.gov NCT02145468) randomized patients with MI to losmapimod or placebo for 12 weeks (24 weeks total...

Cite
Cavender MA, O'Donoghue ML, Abbate A, et al. Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial. Am Heart J. 2021;243:147-157doi: 10.1016/j.ahj.2021.08.022.
Cavender, M. A., O'Donoghue, M. L., Abbate, A., Aylward, P., Fox, K. A., Glaser, R. X., Park, J. G., Lopez-Sendon, J., Steg, P. G., Sabatine, M. S., & Morrow, D. A. (2022). Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial. American heart journal, 243147-157. https://doi.org/10.1016/j.ahj.2021.08.022
Cavender, Matthew A, et al. "Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial." American heart journal vol. 243 (2022): 147-157. doi: https://doi.org/10.1016/j.ahj.2021.08.022
Cavender MA, O'Donoghue ML, Abbate A, Aylward P, Fox KA, Glaser RX, Park JG, Lopez-Sendon J, Steg PG, Sabatine MS, Morrow DA. Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial. Am Heart J. 2022 Jan;243:147-157. doi: 10.1016/j.ahj.2021.08.022. Epub 2021 Sep 08. PMID: 34508693.
Copy Download .nbib Format: NLM
Risk factors for type 2 MI: the usual suspects or guilt by association?.

European heart journal

O'Donoghue ML, Marston NA.
PMID: 34599595
Eur Heart J. 2022 Jan 13;43(2):136-137. doi: 10.1093/eurheartj/ehab707.

No abstract available.

Cite
O'Donoghue ML, Marston NA. Risk factors for type 2 MI: the usual suspects or guilt by association?. Eur Heart J. 2022;43(2):136-137doi: 10.1093/eurheartj/ehab707.
O'Donoghue, M. L., & Marston, N. A. (2022). Risk factors for type 2 MI: the usual suspects or guilt by association?. European heart journal, 43(2), 136-137. https://doi.org/10.1093/eurheartj/ehab707
O'Donoghue, Michelle L, and Marston, Nicholas A. "Risk factors for type 2 MI: the usual suspects or guilt by association?." European heart journal vol. 43,2 (2022): 136-137. doi: https://doi.org/10.1093/eurheartj/ehab707
O'Donoghue ML, Marston NA. Risk factors for type 2 MI: the usual suspects or guilt by association?. Eur Heart J. 2022 Jan 13;43(2):136-137. doi: 10.1093/eurheartj/ehab707. PMID: 34599595.
Copy Download .nbib Format: NLM
Showing 157 to 159 of 159 entries